Safety Profile of IBD: Lymphoma Risks

Gastroenterology Clinics of North America

Volumn 38, Issue 4, 2009, Pages 669-689

  Bewtra, Meenakshi ^a   Lewis, James D ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Hepatosplenic T cell lymphoma; Inflammatory bowel disease; Lymphoma; Thiopurine analogs; TNF antagonists

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CERTOLIZUMAB PEGOL; CORTICOSTEROID; CYCLOSPORIN A; ETANERCEPT; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; PLACEBO; PREDNISONE; TUMOR NECROSIS FACTOR INHIBITOR;

CANCER INCIDENCE; CANCER RISK; CHRONIC DISEASE; CLINICAL TRIAL; CROHN DISEASE; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG DOSE SEQUENCE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG USE; DRUG WITHDRAWAL; ENTERITIS; HEPATOSPLENOMEGALY; HUMAN; IMMUNE DEFICIENCY; IMMUNOSUPPRESSIVE TREATMENT; LEUKOPENIA; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; NONHODGKIN LYMPHOMA; NONHUMAN; PSORIASIS; REVIEW; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SAFETY; T CELL LYMPHOMA; ULCERATIVE COLITIS;

HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; LYMPHOMA; RISK FACTORS; TREATMENT OUTCOME;

EID: 70350780560     PISSN: 08898553     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.gtc.2009.07.004     Document Type: Review

References (130)

1. Baecklund E., Ekbom A., Sparen P., et al. Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control study. BMJ 317 (1998) 180-181
2. Baecklund E., Iliadou A., Askling J., et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum 54 (2006) 692-701
3. Greenstein A.J., Gennuso R., Sachar D.B., et al. Extraintestinal cancers in inflammatory bowel disease. Cancer 56 (1985) 2914-2921
4. Ekbom A., Helmick C., Zack M., et al. Extracolonic malignancies in inflammatory bowel disease. Cancer 67 (1991) 2015-2019
5. Persson P.G., Karlen P., Bernell O., et al. Crohn's disease and cancer: a population-based cohort study. Gastroenterology 107 (1994) 1675-1679
6. Karlen P., Lofberg R., Brostrom O., et al. Increased risk of cancer in ulcerative colitis: a population-based cohort study. Am J Gastroenterol 94 (1999) 1047-1052
7. Mellemkjaer L., Johansen C., Gridley G., et al. Crohn's disease and cancer risk (Denmark). Cancer Causes Control 11 (2000) 145-150
8. Loftus Jr. E.V., Tremaine W.J., Habermann T.M., et al. Risk of lymphoma in inflammatory bowel disease. Am J Gastroenterol 95 (2000) 2308-2312
9. Palli D., Trallori G., Bagnoli S., et al. Hodgkin's disease risk is increased in patients with ulcerative colitis. Gastroenterology 119 (2000) 647-653
10. Farrell R.J., Ang Y., Kileen P., et al. Increased incidence of non-Hodgkin's lymphoma in inflammatory bowel disease patients on immunosuppressive therapy but overall risk is low. Gut 47 (2000) 514-519
11. Bernstein C.N., Blanchard J.F., Kliewer E., et al. Cancer risk in patients with inflammatory bowel disease: a population-based study. Cancer 91 (2001) 854-862
12. Lewis J.D., Bilker W.B., Brensinger C., et al. Inflammatory bowel disease is not associated with an increased risk of lymphoma. Gastroenterology 121 (2001) 1080-1087
13. Winther K.V., Jess T., Langholz E., et al. Long-term risk of cancer in ulcerative colitis: a population-based cohort study from Copenhagen County. Clin Gastroenterol Hepatol 2 (2004) 1088-1095
14. Askling J., Brandt L., Lapidus A., et al. Risk of haematopoietic cancer in patients with inflammatory bowel disease. Gut 54 (2005) 617-622
15. Goldacre M.J., Wotton C.J., Yeates D., et al. Cancer in patients with ulcerative colitis, Crohn's disease and coeliac disease: record linkage study. Eur J Gastroenterol Hepatol 20 (2008) 297-304
16. Hemminki K., Li X., Sundquist J., et al. Cancer risks in ulcerative colitis patients. Int J Cancer 123 (2008) 1417-1421
17. von Roon A.C., Reese G., Teare J., et al. The risk of cancer in patients with Crohn's disease. Dis Colon Rectum 50 (2007) 839-855
18. Ekstrom Smedby K., Vajdic C.M., Falster M., et al. Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph Consortium. Blood 111 (2008) 4029-4038
19. Hakulinen T., Isomaki H., and Knekt P. Rheumatoid arthritis and cancer studies based on linking nationwide registries in Finland. Am J Med 78 (1985) 29-32
20. Prior P. Cancer and rheumatoid arthritis: epidemiologic considerations. Am J Med 78 (1985) 15-21
21. Symmons D.P. Neoplasms of the immune system in rheumatoid arthritis. Am J Med 78 (1985) 22-28
22. Isomaki H.A., Hakulinen T., and Joutsenlahti U. Excess risk of lymphomas, leukemia and myeloma in patients with rheumatoid arthritis. J Chronic Dis 31 (1978) 691-696
23. Gridley G., McLaughlin J.K., Ekbom A., et al. Incidence of cancer among patients with rheumatoid arthritis. J Natl Cancer Inst 85 (1993) 307-311
24. Wolfe F., and Michaud K. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum 50 (2004) 1740-1751
25. Santana V., and Rose N.R. Neoplastic lymphoproliferation in autoimmune disease: an updated review. Clin Immunol Immunopathol 63 (1992) 205-213
26. Hoshida Y., Xu J.X., Fujita S., et al. Lymphoproliferative disorders in rheumatoid arthritis: clinicopathological analysis of 76 cases in relation to methotrexate medication. J Rheumatol 34 (2007) 322-331
27. Silman A.J., Petrie J., Hazleman B., et al. Lymphoproliferative cancer and other malignancy in patients with rheumatoid arthritis treated with azathioprine: a 20 year follow up study. Ann Rheum Dis 47 (1988) 988-992
28. Available at:. http://seer.cancer.gov/index.html Accessed June 13, 2009
29. Engels E.A., Biggar R.J., Hall H.I., et al. Cancer risk in people infected with human immunodeficiency virus in the United States. Int J Cancer 123 (2008) 187-194
30. Mbulaiteye S.M., Biggar R.J., Goedert J.J., et al. Immune deficiency and risk for malignancy among persons with AIDS. J Acquir Immune Defic Syndr 32 (2003) 527-533
31. Biggar R.J., Chaturvedi A.K., Goedert J.J., et al., HIV/AIDS Cancer Match Study. AIDS-related cancer and severity of immunosuppression in persons with AIDS. J Natl Cancer Inst 99 (2007) 962-972
32. Alamartine E., Sabido O., and Berthoux F. In-vitro effects of cyclosporin A, FK506, 6-mercaptopurine, and prednisolone on lymphokine-activated killer cells. Nephrol Dial Transplant 9 (1994) 1456-1461
33. Tamura F., Masuhara A., Sakaida I., et al. FK506 promotes liver regeneration by suppressing natural killer cell activity. J Gastroenterol Hepatol 13 (1998) 703-708
34. Pietersma F., Piriou E., and van Baarle D. Immune surveillance of EBV-infected B cells and the development of non-Hodgkin lymphomas in immunocompromised patients. Leuk Lymphoma 49 (2008) 1028-1041
35. Nalesnik M.A., Jaffe R., Starzl T.E., et al. The pathology of posttransplant lymphoproliferative disorders occurring in the setting of cyclosporine A-prednisone immunosuppression. Am J Pathol 133 (1988) 173-192
36. Kamel O.W., van de Rijn M., Weiss L.M., et al. Brief report: reversible lymphomas associated with Epstein-Barr virus occurring during methotrexate therapy for rheumatoid arthritis and dermatomyositis. N Engl J Med 328 (1993) 1317-1321
37. Paul C., Le Tourneau A., Cayuela J.M., et al. Epstein-Barr virus-associated lymphoproliferative disease during methotrexate therapy for psoriasis. Arch Dermatol 133 (1997) 867-871
38. Losco A., Gianelli U., Cassani B., et al. Epstein-Barr virus-associated lymphoma in Crohn's disease. Inflamm Bowel Dis 10 (2004) 425-429
39. Salloum E., Cooper D.L., Howe G., et al. Spontaneous regression of lymphoproliferative disorders in patients treated with methotrexate for rheumatoid arthritis and other rheumatic diseases. J Clin Oncol 14 (1996) 1943-1949
40. Buell J.F., Gross T.G., and Woodle E.S. Malignancy after transplantation. Transplantation 80 (2005) S254-S264
41. Starzl T.E., Nalesnik M.A., Porter K.A., et al. Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet 1 (1984) 583-587
42. Liote F., Pertuiset E., Cochand-Priollet B., et al. Methotrexate related B lymphoproliferative disease in a patient with rheumatoid arthritis. Role of Epstein-Barr virus infection. J Rheumatol 22 (1995) 1174-1178
43. Viraben R., Brousse P., and Lamant L. Reversible cutaneous lymphoma occurring during methotrexate therapy. Br J Dermatol 135 (1996) 116-118
44. Bachman T.R., Sawitzke A.D., Perkins S.L., et al. Methotrexate-associated lymphoma in patients with rheumatoid arthritis: report of two cases. Arthritis Rheum 39 (1996) 325-329
45. Ladetto M., De Marco F., Benedetti F., et al. Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage. Blood 111 (2008) 4004-4013
46. Kalinka-Warzocha E., Wajs J., Lech-Maranda E., et al. Randomized comparison of cladribine alone or in combination with cyclophosphamide, and cyclophosphamide, vincristine and prednisone in previously untreated low-grade B-cell non-Hodgkin lymphoma patients: final report of the Polish Lymphoma Research Group. Cancer 113 (2008) 367-375
47. Hochster H., Weller E., Gascoyne R.D., et al. Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 study. J Clin Oncol 27 (2009) 1607-1614
48. Lazar A.D., Shpilberg O., Shaklai M., et al. Salvage chemotherapy with dexamethasone, etoposide, ifosfamide and cisplatin (DVIP) for relapsing and refractory non-Hodgkin's lymphoma. Isr Med Assoc J 11 (2009) 16-22
49. Zijlmans J.M., van Rijthoven A.W., Kluin P.M., et al. Epstein-Barr virus-associated lymphoma in a patient with rheumatoid arthritis treated with cyclosporine. N Engl J Med 326 (1992) 1363
50. Cockburn I.T., and Krupp P. The risk of neoplasms in patients treated with cyclosporine A. J Autoimmun 2 (1989) 723-731
51. Paul C.F., Ho V.C., McGeown C., et al. Risk of malignancies in psoriasis patients treated with cyclosporine: a 5 y cohort study. J Invest Dermatol 120 (2003) 211-216
52. Hannuksela-Svahn A., Pukkala E., Laara E., et al. Psoriasis, its treatment, and cancer in a cohort of Finnish patients. J Invest Dermatol 114 (2000) 587-590
53. Shibahara T., Miyazaki K., Sato D., et al. Rectal malignant lymphoma complicating ulcerative colitis treated with long-term cyclosporine A. J Gastroenterol Hepatol 21 (2006) 336-338
54. Schwartz L.K., Kim M.K., Coleman M., et al. Case report: lymphoma arising in an ileal pouch anal anastomosis after immunomodulatory therapy for inflammatory bowel disease. Clin Gastroenterol Hepatol 4 (2006) 1030-1034
55. Rustia M., and Shubik P. Life-span carcinogenicity tests with 4-amino-N10-methylpteroylglutamic acid (methotrexate) in Swiss mice and Syrian golden hamsters. Toxicol Appl Pharmacol 26 (1973) 329-338
56. Shklar G., Cataldo E., and Fitzgerald A.L. The effect of methotrexate on chemical carcinogenesis of hamster buccal pouch. Cancer Res 26 (1966) 2218-2224
57. Khopkar U., and Bhor U. Hodgkin's lymphoma in a patient of psoriasis treated with long-term, low-dose methotrexate therapy. Indian J Dermatol Venereol Leprol 74 (2008) 379-382
58. Ellman M.H., Hurwitz H., Thomas C., et al. Lymphoma developing in a patient with rheumatoid arthritis taking low dose weekly methotrexate. J Rheumatol 18 (1991) 1741-1743
59. Kingsmore S.F., Hall B.D., Allen N.B., et al. Association of methotrexate, rheumatoid arthritis and lymphoma: report of 2 cases and literature review. J Rheumatol 19 (1992) 1462-1465
60. Thomason R.W., Craig F.E., Banks P.M., et al. Epstein-Barr virus and lymphoproliferation in methotrexate-treated rheumatoid arthritis. Mod Pathol 9 (1996) 261-266
61. Ebeo C.T., Girish M.R., Byrd R.P., et al. Methotrexate-induced pulmonary lymphoma. Chest 123 (2003) 2150-2153
62. Suzuki M., Hirano S., Ito H., et al. Pulmonary lymphoma developed during long-term methotrexate therapy for psoriasis. Respirology 12 (2007) 774-776
63. Stern R.S. Lymphoma risk in psoriasis: results of the PUVA follow-up study. Arch Dermatol 142 (2006) 1132-1135
64. Stern R.S., Zierler S., and Parrish J.A. Methotrexate used for psoriasis and the risk of noncutaneous or cutaneous malignancy. Cancer 50 (1982) 869-872
65. Bernatsky S., Clarke A.E., and Suissa S. Hematologic malignant neoplasms after drug exposure in rheumatoid arthritis. Arch Intern Med 168 (2008) 378-381
66. Kinlen L.J., Sheil A.G., Peto J., et al. Collaborative United Kingdom-Australasian study of cancer in patients treated with immunosuppressive drugs. Br Med J 2 (1979) 1461-1466
67. Kinlen L.J. Incidence of cancer in rheumatoid arthritis and other disorders after immunosuppressive treatment. Am J Med 78 (1985) 44-49
68. Pourfarziani V., Taheri S., Lessan-Pezeshki M., et al. Lymphoma after living donor kidney transplantation: an Iranian multicenter experience. Int Urol Nephrol 40 (2008) 1089-1094
69. Asten P., Barrett J., and Symmons D. Risk of developing certain malignancies is related to duration of immunosuppressive drug exposure in patients with rheumatic diseases. J Rheumatol 26 (1999) 1705-1714
70. Present D.H., Meltzer S.J., Krumholz M.P., et al. 6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity. Ann Intern Med 111 (1989) 641-649
71. Connell W.R., Kamm M.A., Dickson M., et al. Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease. Lancet 343 (1994) 1249-1252
72. Bouhnik Y., Lemann M., Mary J.Y., et al. Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. Lancet 347 (1996) 215-219
73. George J., Present D.H., Pou R., et al. The long-term outcome of ulcerative colitis treated with 6-mercaptopurine. Am J Gastroenterol 91 (1996) 1711-1714
74. Korelitz B.I., Mirsky F.J., Fleisher M.R., et al. Malignant neoplasms subsequent to treatment of inflammatory bowel disease with 6-mercaptopurine. Am J Gastroenterol 94 (1999) 3248-3253
75. Dayharsh G.A., Loftus Jr. E.V., Sandborn W.J., et al. Epstein-Barr virus-positive lymphoma in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine. Gastroenterology 122 (2002) 72-77
76. Fraser A.G., Orchard T.R., Robinson E.M., et al. Long-term risk of malignancy after treatment of inflammatory bowel disease with azathioprine. Aliment Pharmacol Ther 16 (2002) 1225-1232
77. Glazier K.D., Palance A.L., Griffel L.H., et al. The ten-year single-center experience with 6-mercaptopurine in the treatment of inflammatory bowel disease. J Clin Gastroenterol 39 (2005) 21-26
78. Kandiel A., Fraser A.G., Korelitz B.I., et al. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut 54 (2005) 1121-1125
79. Bewtra M., and Lichtenstein G.R. Infliximab use in Crohn's disease. Expert Opin Biol Ther 5 (2005) 589-599
80. Sandborn W.J., and Hanauer S.B. Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety. Inflamm Bowel Dis 5 (1999) 119-133
81. Maini R., St. Clair E.W., Breedveld F., et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 354 (1999) 1932-1939
82. Markham A., and Lamb H.M. Infliximab: a review of its use in the management of rheumatoid arthritis. Drugs 59 (2000) 1341-1359
83. Geborek P., Bladstrom A., Turesson C., et al. Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas. Ann Rheum Dis 64 (2005) 699-703
84. Bongartz T., Sutton A.J., Sweeting M.J., et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295 (2006) 2275-2285
85. Matteson E.L., and Bongartz T. Investigation, explanation, and apology for incomplete and erroneous disclosures. JAMA 296 (2006) 2205
86. Targan S.R., Hanauer S.B., van Deventer S.J., et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 337 (1997) 1029-1035
87. Present D.H., Rutgeerts P., Targan S., et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 340 (1999) 1398-1405
88. Rutgeerts P., D'Haens G., Targan S., et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology 117 (1999) 761-769
89. Cohen R.D., Tsang J.F., and Hanauer S.B. Infliximab in Crohn's disease: first anniversary clinical experience. Am J Gastroenterol 95 (2000) 3469-3477
90. Farrell R.J., Shah S.A., Lodhavia P.J., et al. Clinical experience with infliximab therapy in 100 patients with Crohn's disease. Am J Gastroenterol 95 (2000) 3490-3497
91. Ardizzone S., Colombo E., Maconi G., et al. Infliximab in treatment of Crohn's disease: the Milan experience. Dig Liver Dis 34 (2002) 411-418
92. Hanauer S.B., Feagan B.G., Lichtenstein G.R., et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 359 (2002) 1541-1549
93. Wenzl H.H., Reinisch W., Jahnel J., et al. Austrian infliximab experience in Crohn's disease: a nationwide cooperative study with long-term follow-up. Eur J Gastroenterol Hepatol 16 (2004) 767-773
94. Seiderer J., Goke B., and Ochsenkuhn T. Safety aspects of infliximab in inflammatory bowel disease patients. A retrospective cohort study in 100 patients of a German university hospital. Digestion 70 (2004) 3-9
95. Sands B.E., Anderson F.H., Bernstein C.N., et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 350 (2004) 876-885
96. Colombel J.F., Loftus Jr. E.V., Tremaine W.J., et al. The safety profile of infliximab in patients with Crohn's disease: the mayo clinic experience in 500 patients. Gastroenterology 126 (2004) 19-31
97. Ljung T., Karlen P., Schmidt D., et al. Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm County. Gut 53 (2004) 849-853
98. Rutgeerts P., Sandborn W.J., Feagan B.G., et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 353 (2005) 2462-2476
99. Caspersen S., Elkjaer M., Riis L., et al. Infliximab for inflammatory bowel disease in Denmark 1999-2005: clinical outcome and follow-up evaluation of malignancy and mortality. Clin Gastroenterol Hepatol 6 (2008) 1212-1217 quiz 1176
100. Kornbluth A. Infliximab approved for use in Crohn's disease: a report on the FDA GI Advisory Committee conference. Inflamm Bowel Dis 4 (1998) 328-329
101. Ricart E., Panaccione R., Loftus E.V., et al. Infliximab for Crohn's disease in clinical practice at the mayo clinic: the first 100 patients. Am J Gastroenterol 96 (2001) 722-729
102. Brown S.L., Greene M.H., Gershon S.K., et al. Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the food and drug administration. Arthritis Rheum 46 (2002) 3151-3158
103. FDA board document. Update on the TNF-alpha blocking agents; 2003. Available at: (2003). http://proxy.library.upenn.edu:2669/ohrms/dockets/ac/03/briefing/3930b1.htm Accessed June 13, 2009
104. Centocor. Remicade (infliximab) for IV injection. Prescribing information. Available at:. http://www.remicade.com/remicade/global/hcp/hcp_pi.html Accessed June 13, 2009
105. Khanna D., McMahon M., and Furst D.E. Safety of tumour necrosis factor-alpha antagonists. Drug Saf 27 (2004) 307-324
106. Mikuls T.R., and Weaver A.L. Lessons learned in the use of tumor necrosis factor-alpha inhibitors in the treatment of rheumatoid arthritis. Curr Rheumatol Rep 5 (2003) 270-277
107. Scheinfeld N. A comprehensive review and evaluation of the side effects of the tumor necrosis factor alpha blockers etanercept, infliximab and adalimumab. J Dermatolog Treat 15 (2004) 280-294
108. Schiff M.H., Burmester G.R., Kent J.D., et al. Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. Ann Rheum Dis 65 (2006) 889-894
109. Hanauer S.B., Sandborn W.J., Rutgeerts P., et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 130 (2006) 323-333 quiz 591
110. Colombel J.F., Sandborn W.J., Rutgeerts P., et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 132 (2007) 52-65
111. Sandborn W.J., Rutgeerts P., Enns R., et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med 146 (2007) 829-838
112. Humira injection prescribing information and medication guide Jan 2008. Available at: http://proxy.library.upenn.edu:2669/Safety/MedWatch/SafetyInformation/Safety-RelatedDrugLabelingChanges/ucm106686.htm. Accessed June 13, 2009.
113. Schreiber S., Rutgeerts P., Fedorak R.N., et al. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology 129 (2005) 807-818
114. Sandborn W.J., Feagan B.G., Stoinov S., et al. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med 357 (2007) 228-238
115. Schreiber S., Khaliq-Kareemi M., Lawrance I.C., et al. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med 357 (2007) 239-250
116. Peyrin-Biroulet L., Deltenre P., de Suray N., et al. Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol 6 (2008) 644-653
117. Khan W.A., Yu L., Eisenbrey A.B., et al. Hepatosplenic gamma/delta T-cell lymphoma in immunocompromised patients. report of two cases and review of literature. Am J Clin Pathol 116 (2001) 41-50
118. Steurer M., Stauder R., Grunewald K., et al. Hepatosplenic gammadelta-T-cell lymphoma with leukemic course after renal transplantation. Hum Pathol 33 (2002) 253-258
119. Navarro J.T., Ribera J.M., Mate J.L., et al. Hepatosplenic T-gammadelta lymphoma in a patient with Crohn's disease treated with azathioprine. Leuk Lymphoma 44 (2003) 531-533
120. Mackey A.C., Green L., Liang L.C., et al. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J Pediatr Gastroenterol Nutr 44 (2007) 265-267
121. Mittal S., Milner B.J., Johnston P.W., et al. A case of hepatosplenic gamma-delta T-cell lymphoma with a transient response to fludarabine and alemtuzumab. Eur J Haematol 76 (2006) 531-534
122. Thayu M., Markowitz J.E., Mamula P., et al. Hepatosplenic T-cell lymphoma in an adolescent patient after immunomodulator and biologic therapy for Crohn disease. J Pediatr Gastroenterol Nutr 40 (2005) 220-222
123. Shale M., Kanfer E., Panaccione R., et al. Hepatosplenic T cell lymphoma in inflammatory bowel disease. Gut 57 (2008) 1639-1641
124. Lewis J.D., Gelfand J.M., Troxel A.B., et al. Immunosuppressant medications and mortality in inflammatory bowel disease. Am J Gastroenterol 103 (2008) 1428-1435 quiz 1436
125. Siegel C.A., Hur C., Korzenik J.R., et al. Risks and benefits of infliximab for the treatment of Crohn's disease. Clin Gastroenterol Hepatol 4 (2006) 1017-1024 quiz 976
126. Lewis J.D., Schwartz J.S., and Lichtenstein G.R. Azathioprine for maintenance of remission in Crohn's disease: benefits outweigh the risk of lymphoma. Gastroenterology 118 (2000) 1018-1024
127. Johnson F.R., Ozdemir S., Mansfield C., et al. Crohn's disease patients' risk-benefit preferences: serious adverse event risks versus treatment efficacy. Gastroenterology 133 (2007) 769-779
128. Toruner M., Loftus Jr. E.V., Harmsen W.S., et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology 134 (2008) 929-936
129. Van Assche G., Magdelaine-Beuzelin C., D'Haens G., et al. Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology 134 (2008) 1861-1868
130. Sandborn W.J., Rutgeerts P.J., Reinisch W., et al. One year data from the Sonic study: a randomized, double-blind trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. [abstract]. Gastroenterology 136 (2009) A116